Welcome to our dedicated page for Elevance Health SEC filings (Ticker: ELV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elevance Health, Inc. (NYSE: ELV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Elevance Health operates in the direct health and medical insurance carriers industry and uses its SEC reports to present information on financial performance, capital structure, governance, and material events affecting its health benefits and Carelon segments.
Among the most important documents for ELV are its annual reports on Form 10-K and quarterly reports on Form 10-Q. These filings typically include detailed discussions of segment results for Health Benefits and Carelon, membership metrics across commercial, Medicare, Medicaid, and Federal Employee Program lines, risk factors, and management’s analysis of trends in benefit expense ratios, operating expenses, and cash flows. They also describe Elevance Health’s role as a licensee of Blue Cross Blue Shield plans in multiple states and its activities in pharmacy and healthcare services through Carelon.
Elevance Health also files current reports on Form 8-K to disclose specific material events. Recent 8-Ks have covered quarterly earnings releases, reaffirmation of earnings guidance and benefit expense ratio expectations, the election of independent directors to the board and their committee assignments, and a multi-tranche notes offering with maturities extending to 2055. These filings provide insight into governance practices, capital markets activity, and management’s public communications with investors.
Investors interested in executive and board matters can review proxy-related filings and 8-K disclosures regarding director appointments and compensation programs for non-employee directors. Those analyzing Elevance Health’s capital structure can examine registration statements and debt-related exhibits referenced in 8-K filings, which describe terms of senior notes, redemption provisions, and events of default.
On Stock Titan, ELV filings are updated in near real time as they appear in the SEC’s EDGAR system. AI-powered tools summarize lengthy documents such as 10-Ks and 10-Qs, highlight key metrics and risk discussions, and help users quickly locate information on topics like Medicare and Medicaid program exposure, pharmacy and services operations under Carelon, and guidance-related forward-looking statements. Users can also review Form 4 insider transaction reports when available to monitor trading activity by Elevance Health directors and officers.
By using this filings page, investors and researchers can navigate Elevance Health’s regulatory history more efficiently, compare disclosures across reporting periods, and better understand how the company presents its health benefits and services business to regulators and the market.
Elevance Health is asking shareholders to vote at the virtual 2026 Annual Meeting on May 13, 2026, on four proposals, including electing three directors, approving executive pay, ratifying Ernst & Young as auditor, and opposing a political-spending study proposal. The proxy highlights 2025 operating revenue of $197.6 billion, up 13%, operating gain of $7.2 billion, GAAP shareholders’ net income of $5.7 billion and adjusted shareholders’ net income of $6.8 billion. The company returned $4.1 billion to shareholders and paid cash dividends of $6.84 per share, a 5% increase, ending the year with about 45.2 million medical members. The Board emphasizes independent oversight, strong risk and AI governance, sustainability commitments and pay-for-performance, with most executive compensation tied to long-term equity and financial metrics.
The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A reporting 0 shares and 0% beneficial ownership of Elevance Health Inc common stock. The filing states that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Elevance Health, Inc. director Amy W. Schulman reported an open-market sale of common stock. On March 12, 2026, she sold 26 shares of Elevance Health common stock at a price of $287.50 per share. After this transaction, she directly owns 218 shares of Elevance Health common stock.
Elevance Health, Inc. is reaffirming its outlook for 2026 despite potential Medicare sanctions. Company officers plan to tell investors that adjusted shareholders’ earnings for full year 2026 are expected to be at least $25.50 per diluted share. They are also reaffirming a 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points, which reflects expected medical costs as a share of premium revenue.
The Centers for Medicare & Medicaid Services has notified the company of its intent to impose intermediate sanctions on certain Medicare Advantage-Prescription Drug plans effective March 31, 2026, unless identified issues are resolved. The reaffirmed earnings and benefit expense ratio guidance already incorporates the potential impact of these sanctions, if imposed. Elevance Health states it cannot reasonably estimate any potential financial payments to resolve this matter, so it is not providing a reconciliation from adjusted earnings per diluted share to the comparable GAAP measure.
Elevance Health, Inc. executive Kendrick Charles Morgan Jr., EVP & President, Commercial, reported an open-market sale of common stock. On March 6, 2026, he sold 3,196 shares at a weighted average price of $284.92 per share, and held 11,791 shares afterward.
Rule 144 notice filed reporting proposed sales of company stock tied to equity awards. The filing lists proposed transactions for Common shares tied to restricted stock and performance shares with trade dates 03/01/2026 and 03/03/2026.
The itemized quantities shown include 522, 481, 1,701, and 492 shares across the award types. The broker/dealer listed is Morgan Stanley Smith Barney LLC, New York Plaza, and the form references ELV on the NYSE.
Elevance Health director Steven H. Collis reported an open-market purchase of common stock. On March 5, 2026, he bought 3,000 shares of Elevance Health at an average price of $289.84 per share. Following this transaction, he directly owns 3,639 common shares of the company.
Elevance Health chief accounting officer and controller Ronald W. Penczek reported several equity award changes. On March 2, 2026, he acquired common stock through grants and restricted share units, plus an employee stock option for 1,677 shares that vests in three annual installments starting on March 2, 2027. On March 2 and March 3, 2026, he disposed of small amounts of common stock through tax-withholding transactions tied to the vesting of previously granted restricted stock, rather than open-market sales. Footnotes show additional restricted share units with restrictions lapsing between 2027 and 2029, and participation in a dividend reinvestment plan in 2025.
Elevance Health EVP & Chief Legal Officer Erin M. Wessling reported equity compensation changes. On March 2, 2026, she received 2,976 shares of common stock as restricted share units and an option for 11,754 shares, vesting in three annual installments starting March 2, 2027. On March 3, 2026, 417 shares of common stock were disposed of at $284.03 per share to cover tax withholding upon vesting of previously granted restricted stock, leaving her with 7,579 common shares held directly.
Elevance Health EVP & Chief HR Officer Craig Ryan R reported multiple equity transactions. On March 2, 2026, he received an award of 11,754 employee stock options at an exercise price of $0.0000 per share, exercisable in three annual installments of 3,918 options beginning on March 2, 2027. He also acquired 2,976 shares of common stock as a grant, described as restricted share units with restrictions lapsing in three installments of 992 shares on March 2, 2027, March 2, 2028, and March 2, 2029. On March 2 and 3, 2026, a total of 334 common shares were disposed of at prices of $294.07 and $284.03 per share, respectively, as tax-withholding dispositions to cover liabilities upon vesting of previously granted restricted stock, rather than open‑market sales.